<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Curr Neurol Neurosci Rep</journal-id>
<journal-id journal-id-type="iso-abbrev">Curr Neurol Neurosci Rep</journal-id>
<journal-title-group>
<journal-title>Current Neurology and Neuroscience Reports</journal-title>
</journal-title-group>
<issn pub-type="ppub">1528-4042</issn>
<issn pub-type="epub">1534-6293</issn>
<publisher>
<publisher-name>Springer US</publisher-name>
<publisher-loc>New York</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28733970</article-id>
<article-id pub-id-type="pmc">5522513</article-id>
<article-id pub-id-type="publisher-id">780</article-id>
<article-id pub-id-type="doi">10.1007/s11910-017-0780-8</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Genetics (V Bonifati, Section Editor)</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>New Genes Causing Hereditary Parkinson’s Disease or
Parkinsonism</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Puschmann</surname>
<given-names>Andreas</given-names>
</name>
<address>
<phone>+46-46-171000</phone>
<email>Andreas.Puschmann@med.lu.se</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0930 2361</institution-id><institution-id institution-id-type="GRID">grid.4514.4</institution-id><institution>Lund University, Skåne University Hospital, </institution><institution>Department of Clinical Sciences Lund, Neurology, </institution></institution-wrap>Lund, Sweden </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.411843.b</institution-id><institution>Department for Neurology, </institution><institution>Skåne University Hospital, </institution></institution-wrap>Getingevägen 4, 224 67 Lund, Sweden </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>21</day>
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>21</day>
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2017</year>
</pub-date>
<volume>17</volume>
<issue>9</issue>
<elocation-id>66</elocation-id>
<permissions>
<copyright-statement>© The Author(s) 2017</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold> This article is distributed under the
terms of the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appropriate credit
to the original author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<sec>
<title>Purpose of Review</title>
<p id="Par1">This article reviews genes where putative or confirmed pathogenic
mutations causing Parkinson’s disease or Parkinsonism have been identified since
2012, and summarizes the clinical and pathological picture of the associated
disease subtypes.</p>
</sec>
<sec>
<title>Recent Findings</title>
<p id="Par2">Newly reported genes for dominant Parkinson’s disease are <italic>DNAJC13</italic>, <italic>CHCHD2</italic>, and
<italic>TMEM230</italic>. However, the evidence for a
disease-causing role is not conclusive, and further genetic and functional studies
are warranted. <italic>RIC3</italic> mutations have been
reported from one family but not yet encountered in other patients. New genes for
autosomal recessive disease include <italic>SYNJ1</italic>,
<italic>DNAJC6</italic>, <italic>VPS13C</italic>, and <italic>PTRHD1.</italic> Deletions of
a region on chromosome 22 (22q11.2del) are also associated with early-onset PD,
but the mode of inheritance and the underlying causative gene remain unclear.
<italic>PODXL</italic> mutations were reported in autosomal
recessive PD, but their roles remain to be confirmed. Mutations in <italic>RAB39B</italic> cause an X-linked Parkinsonian disorder<italic>.</italic>
</p>
</sec>
<sec>
<title>Summary</title>
<p id="Par3">Mutations in the new dominant PD genes have generally been found in
medium- to late-onset Parkinson’s disease. Many mutations in the new recessive and
X-chromosomal genes cause severe atypical juvenile Parkinsonism, but less
devastating mutations in these genes may cause PD.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Parkinson’s disease</kwd>
<kwd>Parkinsonism</kwd>
<kwd>Dominant</kwd>
<kwd>Recessive</kwd>
<kwd>Monogenic</kwd>
<kwd>Genetic</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution>Lund University</institution>
</funding-source>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© Springer Science+Business Media, LLC 2017</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Introduction</title>
<p id="Par4">Since the discovery of the first gene for Parkinson’s disease (PD)
20 years ago, a large number of additional genes have been implicated as monogenic
causes for PD, or for disorders with Parkinsonism as a more or less prominent
clinical feature. Today, genetic testing of patients with young-onset, hereditary or
unusual Parkinsonian disorders has become part of clinical practice in many
healthcare settings. This review attempts to evaluate the reports since 2012 on new
genes with mutations associated with monogenic PD or Parkinsonism, concentrating on
the clinical and pathological descriptions of these new forms of disease. For
reasons of space, this review does not include new results on PD genes identified
before 2012, where new results acquired in recent years have consolidated, expanded,
and sometimes refuted previous knowledge. Readers are referred to broader previous
reviews that summarize the knowledge in the field available at the time of their
writing [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR6">6</xref>].</p>
</sec>
<sec id="Sec2">
<title>New Genes for Dominant PD</title>
<p id="Par5">Since 2012, mutations in <italic>DNAJC13</italic>,
<italic>CHCHD2</italic>, <italic>TMEM230</italic>, and <italic>RIC3</italic> have been
reported as new causes for monogenic dominant PD. The following sections provide a
review of the available reports on the clinical picture and genetic information. All
of these discoveries are recent, and it is today not definitely proven that
mutations in these genes cause PD. The present evidence appears most robust for a
causative role of <italic>CHCHD2</italic> mutations in PD because
of the description of more than one family with co-segregation of clinical phenotype
and genotype, but less robust for <italic>DNAJC13</italic> and
<italic>TMEM230</italic>, because these mutations were found in
only one, albeit large, pedigree, and least robust for <italic>RIC3</italic> that has only been reported from one less extensive family. Table
<xref ref-type="table" rid="Tab1">1</xref> provides an overview over presently
known genes for dominant PD, which generally cause medium- to late-onset
Parkinsonism or PD, for most genes with few or no additional features.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Monogenic causes for autosomal dominant Parkinson’s
disease</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene</th><th>Year</th><th>Additional clinical features besides Parkinsonism</th></tr></thead><tbody><tr><td>
<bold><italic>SNCA</italic></bold>
</td><td>1997</td><td>Cognitive, behavioral, and autonomic dysfunction,
myoclonus</td></tr><tr><td>
<bold><italic>LRRK2</italic></bold>
</td><td>2004</td><td>Few, variable. Possibly only milder non-motor
disturbances</td></tr><tr><td>
<italic>EIF4G1</italic>
</td><td>2011</td><td>Probably not pathogenic</td></tr><tr><td>
<bold><italic>VPS35</italic></bold>
</td><td>2011</td><td>Cognitive and behavioral changes (?)</td></tr><tr><td>
<italic>DNAJC13</italic>
</td><td>2013</td><td>None</td></tr><tr><td>
<italic>CHCHD2</italic>
</td><td>2015</td><td>None. Two carriers with tremor only</td></tr><tr><td>
<italic>TMEM230</italic>
</td><td>2016</td><td>One large family only</td></tr><tr><td>
<italic>RIC3</italic>
</td><td>2016</td><td>One family only</td></tr></tbody></table><table-wrap-foot><p>Gene names not in bold print indicate that pathogenicity remains
unconfirmed</p></table-wrap-foot></table-wrap>
</p>
<sec id="Sec3">
<title>DNAJC13</title>
<p id="Par6">In 2013, Vilariño-Güell et al. identified c.2564A&gt;G (p.N855S)
mutations in <italic>DNAJC13</italic> in a large family with
autosomal dominant PD. Eleven PD patients from two successive generations carried
these mutations, whereas one family member with progressive supranuclear palsy and
two additional members with PD did not. DNAJC13 p.N855S mutations were also
identified in two additional familial and three sporadic cases from Canada
[<xref ref-type="bibr" rid="CR7">7</xref>••, <xref ref-type="bibr" rid="CR8">8</xref>], but not in other populations so far [<xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR11">11</xref>]. A recent follow-up study identified three
additional members of the original family who had become symptomatic by that time
[<xref ref-type="bibr" rid="CR12">12</xref>]. All known carriers reside in
Saskatchewan or British Columbia, Canada, and reported Dutch-German-Russian
Mennonite origin, strongly suggesting a common founder. This was supported by
results of genetic comparisons of the haplotype surrounding the disease-causing
mutation [<xref ref-type="bibr" rid="CR7">7</xref>••].</p>
<p id="Par7">The clinical phenotype of DNAJC p.N855S carriers was described as
clinically definite Parkinson’s disease in 13 out of the 17 patients reported so
far [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. The remaining four patients had relatively mild disease with
rigidity and bradykinesia as well as action or postural tremor, but no resting
tremor. Six patients, including all who only had action or postural tremor, did
not require levodopa treatment at all, despite disease durations of up to
20 years. Symptom onset was between 40 and 85 years (mean 63.2; standard
deviation, S.D., 12.5), and disease progression was generally slow. Patients in
earlier disease stages responded to levodopa, but patients at late disease stage
(Hoehn and Yahr 4) did not [<xref ref-type="bibr" rid="CR12">12</xref>].
Multitracer PET examinations revealed a dopaminergic deficit in the striatum with
a pattern as in idiopathic PD, affecting the putamen more than the caudate
[<xref ref-type="bibr" rid="CR12">12</xref>]. Three mutation carriers from
the original kindred have been examined neuropathologically after disease
durations of 8 to 17 years. All had alpha-synuclein-positive Lewy body pathology
with cell loss in the basal nucleus of Meynert and substantia nigra, and the
distribution of alpha-synuclein pathology was brainstem only in one and
transitional in two. All three showed tau pathology with neurofibrillary tangles
including hippocampal involvement and arteriosclerotic vascular disease. Two
patients had evidence of cerebrovascular accidents [<xref ref-type="bibr" rid="CR7">7</xref>••, <xref ref-type="bibr" rid="CR12">12</xref>]. DNAJC13
p.N855S mutations are rare events [<xref ref-type="bibr" rid="CR10">10</xref>].</p>
<p id="Par8">Another mutation in <italic>DNAJC13</italic>,
c.6344G&gt;T (p.R2115L), was identified in two patients and one unaffected member
of one Tunisian family [<xref ref-type="bibr" rid="CR7">7</xref>••]. It is
uncertain if this mutation is pathogenic. DNAJC13 protein is present on endosomal
membranes where it is involved in clathrin coating of early endosomes.
p.A855S-mutated DNAJC13 impairs endosomal transport by a toxic gain-of-function
mechanism [<xref ref-type="bibr" rid="CR7">7</xref>••].</p>
<p id="Par9">No coding variants in <italic>DNAJC13</italic>
were detected when the gene was sequenced in 1938 Caucasian PD cases and 838
patients with pathologically confirmed Lewy body disease [<xref ref-type="bibr" rid="CR10">10</xref>]. Variants in the gene have been identified
as PD susceptibility factors [<xref ref-type="bibr" rid="CR8">8</xref>,
<xref ref-type="bibr" rid="CR11">11</xref>].</p>
</sec>
<sec id="Sec4">
<title>CHCHD2</title>
<p id="Par10">In 2015, Funayama et al. reported <italic>CHCHD2</italic> c.182C&gt;T (p.T61I) mutations in a large Japanese family
with ten affected mutation carriers in two successive generations. The same
mutation was found in a different family with autosomal dominant PD where,
interestingly, one of the mutation carriers had fine tremor since age 10, but no
Parkinsonism at age 50 [<xref ref-type="bibr" rid="CR13">13</xref>••]. Seven
of nine mutation carriers with PD had been treated with levodopa, and all had good
response. Two of ten patients described had hyperreflexia. This mutation was also
found in two affected siblings from a Chinese family with seemingly autosomal
dominant PD. Also in this family, a third sibling carried the p.T61I mutation and
had only mild tremor from age 39 and a symptomatology compatible with essential
tremor 3 years later, without overt Parkinsonism [<xref ref-type="bibr" rid="CR14">14</xref>]. PET studies showed mildly reduced dopamine reuptake in the
posterior putamen in this individual, and more markedly reduced dopamine uptake in
the putamen and the caudate nucleus in an affected brother [<xref ref-type="bibr" rid="CR15">15</xref>]. Two of seven patients from the Chinese
family had dysphagia, one displayed a positive Babinski sign and one had
electrophysiological evidence for neurogenic muscle degeneration. The average age
at symptom onset in the three families combined was 52 years (S.D. 5.8; range
40–61) [<xref ref-type="bibr" rid="CR13">13</xref>••, <xref ref-type="bibr" rid="CR14">14</xref>], and typically there was asymmetric
bradykinesia, rigidity, and resting tremor that responded well to levodopa. No
neuropathology of patients with <italic>CHCHD2</italic>
mutations has so far been reported.</p>
<p id="Par11">Several other studies have since examined the <italic>CHCHD2</italic> gene in patients and controls. From Germany, a
PD patient with <italic>CHCHD2</italic> c.376C&gt;T (p.Gln126X)
mutation has been reported and this mutation has been suggested to be pathogenic
as it leads to protein truncation [<xref ref-type="bibr" rid="CR16">16</xref>]. Other rare variants mutations in <italic>CHCHD2</italic> have been identified in PD patients, but their pathogenicity
remains more uncertain [<xref ref-type="bibr" rid="CR13">13</xref>••,
<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], and <italic>CHCHD2</italic> variants have
been shown to increase PD risk [<xref ref-type="bibr" rid="CR18">18</xref>].
In total, more than 4100 PD cases and more than 1900 unaffected controls have been
analyzed to date [<xref ref-type="bibr" rid="CR13">13</xref>••, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR16">16</xref>–<xref ref-type="bibr" rid="CR25">25</xref>]. Definite confirmation of the pathogenicity of <italic>CHCHD2</italic> mutations is currently lacking.</p>
</sec>
<sec id="Sec5">
<title>RIC3</title>
<p id="Par12">In a three-generational family from Karnataka State in Southern
India, Sudhaman et al. identified RIC3 c.169C&gt;A (p.P57T) mutations
[<xref ref-type="bibr" rid="CR26">26</xref>]. In this family, five members
in two generations had bradykinesia and rigidity, and two of these also tremors
and the oldest individual had Parkinsonism and dystonia. The average age at onset
was 60 years (S.D. 5.2, range 54–68). Four of these individuals also had restless
legs syndrome, and two REM-sleep behavior disorder. An additional member with PD
was deceased at the time of study. Four members of the successive generation
displayed very mild signs such as reduced arm swing, bradykinesia, and/or rigidity
on clinical examination at age 26 to 40 years, while five of their siblings and
cousins did not show any movement disorder. RIC3 p.P57T mutations were present in
all nine affected members and absent in all five unaffected members tested
[<xref ref-type="bibr" rid="CR26">26</xref>]. The fact that only mild
symptoms were reported from the only reported family’s third generation opens up
for the possibility that some of these individuals may not develop PD, and
conversely, some of their younger siblings or cousins may still develop the
disease. No additional kindred with mutations in <italic>RIC3</italic> has so far been identified; why the pathogenicity of <italic>RIC3</italic> mutations for PD remains unconfirmed. Variants in
<italic>RIC3</italic> have not been associated with PD in one
case-control study performed to date [<xref ref-type="bibr" rid="CR27">27</xref>].</p>
</sec>
<sec id="Sec6">
<title>TMEM230</title>
<p id="Par13">In 2016, Deng et al. reported the results of their independent
analysis of the same Canadian Mennonite kindred where Vilariño-Güell et al.
previously found mutations in <italic>DNAJC13</italic> (see
above) [<xref ref-type="bibr" rid="CR7">7</xref>••, <xref ref-type="bibr" rid="CR28">28</xref>••]<italic>.</italic> Deng
et al. instead identified <italic>TMEM230</italic> c.422G&gt;T
(p.R141L) as the cause of the disease in that kindred. They emphasized the fact
that two family members with PD and one with progressive supranuclear palsy did
not carry <italic>DNAJC13</italic> mutations, whereas all
affected individuals they tested carried <italic>TMEM230</italic> mutations. No additional large family with clear
co-segregation of a <italic>TMEM230</italic> mutation and PD has
been identified.</p>
<p id="Par14">Deng et al. also identified three additional <italic>TMEM230</italic> variants in PD patients, among them <italic>TMEM230</italic> c.550_552delTAGinsCCCGGG (p.*184ProGlyext*5).
This mutation was unusually common among Chinese PD families, reported from 7 out
of 574 families, who were either homozygous or heterozygous carriers, and
co-segregated with PD in two affected sib-pairs from these seven families
[<xref ref-type="bibr" rid="CR28">28</xref>••, <xref ref-type="bibr" rid="CR29">29</xref>]. Several additional studies examining large
series of PD patients, mostly of Caucasian and Chinese origin, have remained
negative and have not identified the p.*184ProGlyext*5 variant [<xref ref-type="bibr" rid="CR30">30</xref>–<xref ref-type="bibr" rid="CR39">39</xref>]. The pathogenicity of <italic>TMEM230</italic> variants needs to be considered unconfirmed.</p>
</sec>
</sec>
<sec id="Sec7">
<title>New Genes for Recessive and X-Linked PD or Parkinsonism</title>
<p id="Par15">Compared to monogenic dominant PD and to the well-established
recessive early-onset PD genes <italic>PARK2</italic>, <italic>DJ-1</italic>, and <italic>PINK1</italic>, the
newly identified recessive forms appear more complex both for clinicians and
researchers. The clinical picture of the newly identified recessive forms is often
more severe and multifaceted. However, in a few instances, there appears to be a
genotype-phenotype correlation where mutations that lead to pronounced alteration of
normal protein function cause a complex disorder with severe additional neurological
or neuropsychiatric impairment, often from birth, and juvenile Parkinsonism, whereas
mutations with a milder effect on the protein cause Parkinsonism with fewer atypical
features. Table <xref ref-type="table" rid="Tab2">2</xref> summarizes currently known
and putative genes for recessive and X-linked PD or Parkinsonism.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Monogenic causes for autosomal recessive or X-linked Parkinson’s
disease or atypical juvenile Parkinsonism</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene</th><th>Year</th><th>Atypical clinical features</th></tr></thead><tbody><tr><td>
<bold><italic>PARK2</italic></bold>
<bold>(</bold>
<bold><italic>Parkin</italic></bold>
<bold>)</bold>
</td><td>1998</td><td>None</td></tr><tr><td>
<bold><italic>DJ-1</italic></bold>
</td><td>2003</td><td>None. Psychiatric features, dystonia (in some
patients)</td></tr><tr><td>
<bold><italic>PINK1</italic></bold>
</td><td>2004</td><td>None. Cognitive/psychiatric symptoms (in some
patients)</td></tr><tr><td>
<bold><italic>FBXO7</italic></bold>
</td><td>2008</td><td>Spasticity, equinovarus deformity (in some
patients)</td></tr><tr><td>
<bold><italic>22q11.2del</italic></bold>
</td><td>2013</td><td>Intellectual disability</td></tr><tr><td>
<bold><italic>SYNJ1</italic></bold>
</td><td>2013</td><td>Dystonia, cognitive decline, seizures</td></tr><tr><td>
<bold><italic>RAB39B</italic></bold>
</td><td>2014</td><td>Severe intellectual disability. X-linked mode of
inheritance</td></tr><tr><td>
<bold><italic>DNAJC6</italic></bold>
</td><td>2015</td><td>Intellectual disability, other neurological
features</td></tr><tr><td>
<italic>PODXL</italic>
</td><td>2016</td><td>None. One family only. To be confirmed in independent
studies</td></tr><tr><td>
<bold><italic>VPS13C</italic></bold>
</td><td>2016</td><td>Severe cognitive dysfunction, tetraplegia</td></tr><tr><td>
<bold><italic>PTRHD1</italic></bold>
</td><td>2017</td><td>Severe cognitive dysfunction, muscular weakness</td></tr></tbody></table><table-wrap-foot><p>Mutations in additional genes have long been known to cause
recessive neurological diseases that in various proportions of patients may
cause Parkinsonism [<xref ref-type="bibr" rid="CR2">2</xref>,
<xref ref-type="bibr" rid="CR4">4</xref>]. These syndromes are not
included here since they are clearly distinguishable from PD clinically,
and/or not newly identified since 2012. Gene names not in bold print indicate
that pathogenicity remains unconfirmed</p></table-wrap-foot></table-wrap>
</p>
<sec id="Sec8">
<title>22q11.2 Deletion Syndrome</title>
<p id="Par16">Hemizygous deletions of a segment within the 11.2 band on the long
arm of chromosome 22 are known to cause a clinical syndrome, 22q11.2 deletion
syndrome, with very variable signs and symptoms, often including learning
difficulties, midline developmental abnormalities, especially of the palate,
larynx, trachea, and/or esophagus, subtle facial dysmorphies, and deficiencies of
the immune system [<xref ref-type="bibr" rid="CR40">40</xref>]. Autism
spectrum disorder or schizophrenia is a common manifestation, as well as
relatively milder disturbances such as difficulties with social interaction,
anxiety, or attention deficit disorder. There may be hypocalcemia and renal or
skeletal abnormalities. The designation 22q11.2 deletion syndrome includes
phenotypes previously known as velocardiofacial syndrome and DiGeorge syndrome.
22q11.2 deletion syndrome is considered to be the most common microdeletion
syndrome in humans, occurring in more than 1 per 4000 births. The majority of
patients have a deletion of 3 million base pairs, encompassing about 40 genes, but
a minority have shorter nested deletions. Many of the anomalies are present from
birth, but some of the other symptoms, especially the psychiatric symptoms, may
develop in mid-adult life [<xref ref-type="bibr" rid="CR40">40</xref>].</p>
<p id="Par17">Parkinsonism had already been described between 1998 and 2010 in
four patients with this syndrome [<xref ref-type="bibr" rid="CR41">41</xref>–<xref ref-type="bibr" rid="CR43">43</xref>]. In 2013, Butcher et al. reported additional three unrelated
patients with 22q11.2 deletion syndrome and Parkinsonism, and, importantly,
provided the results of a neuropathological examination of three patients
[<xref ref-type="bibr" rid="CR44">44</xref>]. Two of these had cell loss in
the substantia nigra and prominent alpha-synuclein-positive Lewy bodies in the
brainstem; one patient had marked cell loss in the substantia nigra, locus
coeruleus, and dorsal nucleus of the vagal nerve but without alpha-synuclein
pathology. There was also amyloid and tau pathology. The findings confirmed the
presence of the neurodegenerative process typical for PD and ruled out that all
Parkinsonian signs and symptoms were solely induced by neuroleptic treatment for
the psychiatric disease manifestations. Case reports and small case series on six
additional patients have been published since [<xref ref-type="bibr" rid="CR45">45</xref>–<xref ref-type="bibr" rid="CR49">49</xref>].</p>
<p id="Par18">The clinical phenotype of these patients included Parkinsonism,
starting at a mean of 41 years (S.D. 8) of age, often with resting tremor or gait
disturbance. There was good response to levodopa or other dopaminergic treatment,
which often was combined with withdrawal of antipsychotic medication, and early
development of motor fluctuations was reported. Frequently, worsening of psychotic
symptoms limited the dose of dopaminergic medications. However, all patients
reported in these reports had marked additional symptoms such as severe and
difficult-to-treat psychosis or schizophrenia, learning disabilities, or obvious
midline imaging anomalies. These additional features were usually present from
birth or childhood or young adult age, long before Parkinsonian signs were noted.
SPECT examinations have been reported from six patients who all showed bilaterally
reduced dopaminergic reuptake in the striatum [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. MRI brain imaging has shown cava septi
vergae, white matter hyperintensities in T2, and reduced brainstem volume in these
case reports. MIBG scintigraphy was performed in one patient and showed normal
cardiac autonomous innervation [<xref ref-type="bibr" rid="CR48">48</xref>].</p>
<p id="Par19">In a large multicenter case-control study, Mok et al. addressed the
question whether hemizygous 22q11.2 deletions are associated with idiopathic PD.
Among 9387 patients enrolled in their case series with a clinical diagnosis of PD,
eight were found to be hemizygous carriers of 22q11.2 deletions; no such deletion
was found among 13,863 control subjects [<xref ref-type="bibr" rid="CR50">50</xref>]. The eight mutation carriers had developed Parkinsonian signs
or symptoms at a median of 37 years. Given the large scale of the study, detailed
individual data was not available for each of the mutation carriers, but
retrospectively other features of 22q11.2 deletion syndrome were present in all of
the mutation carriers, although they may have been mild at the time of inclusion
in the study, and may not have been specifically asked for at the time of
enrollment in research studies focused on PD [<xref ref-type="bibr" rid="CR50">50</xref>].</p>
<p id="Par20">Patients with hemizygous 22q11.2 deletions also showed additional
movement disorder phenomena, such as postural and action tremor, myoclonic jerks,
and intermittent oculogyric movements, alone or in combination with Parkinsonian
signs [<xref ref-type="bibr" rid="CR46">46</xref>]. Medical treatment of the
symptoms of 22q11.2 deletion syndrome requires a careful balance of
antiparkinsonian and antipsychotic agents, and the readiness to accept suboptimal
treatment responses regarding both Parkinsonism and psychosis.</p>
<p id="Par21">Presently, it is not known which mutation(s) in which of the genes
in the deleted segment causes the development of Parkinsonism in these patients,
or if the microdeletion per se is causative. Several possible candidate genes have
been suggested [<xref ref-type="bibr" rid="CR51">51</xref>]. All patients
with 22q11.2 deletion syndrome for whom the extent of the deletion was examined
showed forms of the long, 2.8 to 3.0 million base pair deletion, and not the rarer
shorter deletions [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. One additional PD patient with a shorter, atypical deletion
of only 726 kb length was reported but not considered to represent 22q11.2
deletion syndrome; this deletion overlapped only to a small part with the area
usually deleted in the shorter deletions [<xref ref-type="bibr" rid="CR30">30</xref>].</p>
<p id="Par22">Investigation for 22q11.2 deletions was suggested in the diagnostic
workup of patients with early-onset PD who have congenital palatal or cardiac
defects, recurrent infections or other signs of immune deficiency, late
developmental milestones, or marked psychiatric comorbidity [<xref ref-type="bibr" rid="CR49">49</xref>]. It has been pointed out that early
detection of 22q11.2 deletions might be beneficial for timely recognition and
treatment of manifestations such as hypocalcemia, abnormal thyroid or parathyroid
function, abnormal magnesium levels, or cardiac abnormalities [<xref ref-type="bibr" rid="CR49">49</xref>].</p>
</sec>
<sec id="Sec9">
<title>SYNJ1</title>
<p id="Par23">Quadri et al. and Krebs et al. simultaneously described two
families with homozygous mutations c.773G&gt;A (p.R258G) in the <italic>SYNJ1</italic> gene [<xref ref-type="bibr" rid="CR52">52</xref>••, <xref ref-type="bibr" rid="CR53">53</xref>••]. In each
of the two families, one from Sicily and one from Iran, there were two affected
siblings, and parents were consanguineous. In the Italian family, one son
developed slowness of movements, leg stiffness, fatigue, and upper arm involuntary
movements at age 22 years. He soon became unable to walk and to work and within
3 years lost his ability to talk. Dystonia, irregular tremor, eyelid apraxia, and
supranuclear vertical gaze limitation were noted. Levodopa was ineffective but
worsened the oromandibular and limb dystonia. The patient had severe cognitive
dysfunction. Symptom progression was unusually rapid initially, but after more
than two decades, the disorder remained generally stable, with some degree of
fluctuation [<xref ref-type="bibr" rid="CR54">54</xref>]. His sister had
similar but perhaps somewhat milder symptoms starting at 28 years. MRI showed
cerebral cortical atrophy, quadrigeminal plate thinning, and hippocampal T2
hyperintensity. Further imaging showed nigrostriatal dopaminergic deficit and
cortical hypometabolism [<xref ref-type="bibr" rid="CR52">52</xref>••]. The
two siblings from the Iranian family additionally had seizures during infancy and
from the age of 3 years, respectively. The developed a severe progressive
Parkinsonian syndrome with chin tremor in their 20s. They had oculomotor
abnormalities and severe hypophonia. A short but marked improvement after
administration of low levodopa doses (25 mg) was noted in one of the patients
whereas his sister developed dyskinesia at the same dose. Cognitive function was
considered normal. MRI showed cortical atrophy and white matter abnormalities. One
of the siblings had a meningioma, impressing on the brainstem why interpretation
of the symptoms is difficult [<xref ref-type="bibr" rid="CR53">53</xref>••].</p>
<p id="Par24">A third family with the same SYNJ1 R258G mutation, also from
Southern Italy, was identified soon thereafter [<xref ref-type="bibr" rid="CR55">55</xref>]. Their clinical presentation was similar to the previous
families, but the two siblings had reached developmental milestones of childhood
development somewhat late. No abnormalities on MRI could be discerned. Follow-up
examinations after 4 and 7 years of disease duration showed progress of
Parkinsonism, albeit not unusually rapid, depression, and progressive cognitive
impairment. There were no indications for REM-sleep behavioral disorder, and MIBG
scintigraphy showed normal cardiac sympathetic innervation [<xref ref-type="bibr" rid="CR56">56</xref>].</p>
<p id="Par25">A different <italic>SYNJ1</italic> mutation,
c.1376C&gt;G (p.R459P), has since been identified in a consanguineous Indian
family from Jharkhand state [<xref ref-type="bibr" rid="CR57">57</xref>]. The
two affected individuals had developed tremor and at age 12 and 18 years developed
Parkinsonism that was alleviated by levodopa, dystonia, and dyskinesia but had not
developed dementia after 4 and 20 years of disease duration.</p>
<p id="Par26">Two German siblings, compound heterozygous for two different
<italic>SYNJ1</italic> mutations c.512G&gt;A (p.W171*) and
c.773G&gt;A (p.R258G), had seizures within the first 4 years of life, and
developed generalized, dopa-responsive dystonia at ages 13 and 15 years, with
action tremor of the tongue, head, and extremities. One of them had reached
developmental milestones late, both had cognitive dysfunction in early adult life.
CSF analyses showed signs associated with impairments in dopamine synthesis,
including decreased homovanillic acid and tetrahydrobiopterin [<xref ref-type="bibr" rid="CR58">58</xref>].</p>
<p id="Par27">Other <italic>SYNJ1</italic> mutations cause a
recessive epilepsy syndrome with progressive and very severe neurological decline
during the first years of life [<xref ref-type="bibr" rid="CR59">59</xref>,
<xref ref-type="bibr" rid="CR60">60</xref>]. It has been noted that
mutations associated with Parkinsonism affect the protein’s SAC1-like domain,
whereas mutations causing the severe epilepsy syndrome impair the protein’s dual
phosphatase activity [<xref ref-type="bibr" rid="CR53">53</xref>••,
<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR57">57</xref>–<xref ref-type="bibr" rid="CR60">60</xref>].</p>
<p id="Par28">No pathology has been reported from a patient with <italic>SYNJ</italic>-related Parkinsonism, but one Pakistani child with
SYNJ1 c.406C&gt;T, p.R136X mutations, and a most severe neurodevelopmental
syndrome with intractable epilepsy was examined neuropathologically after death at
age 6.5 years. Macroscopically, there was general white matter atrophy but,
remarkably, the most prominent pathology on microscopic examination was found in
the substantia nigra: There was marked cell loss, and intensely positive tau
pathology with neurofibrillary tangles, in cell bodies, axonal hillocks, and
neuropil threads. Similar but milder pathology was found in the basal ganglia.
There was no immunoreactivity to alpha-synuclein [<xref ref-type="bibr" rid="CR59">59</xref>]. The parkinsonian patients with <italic>SYNJ1</italic> mutation showed clinical and radiological signs reminiscent of
other tauopathies, such as vertical gaze palsy and atrophy of the quadrigeminal
plate, suggesting that a tauopathy might be the underlying cause.</p>
<p id="Par29">Recently, Taghavi et al. reported a SYNJ1 p.R839C mutation in a
small Iranian family with two affected siblings with poorly levodopa-responsive
Parkinsonism and generalized seizures since 24 years of age. Longitudinal fissures
were present on the tongue of this family’s index patient and were thereafter also
noticed on the tongue of a previously described Iranian patient carrying SYNJ1
p.R258G [<xref ref-type="bibr" rid="CR53">53</xref>••, <xref ref-type="bibr" rid="CR61">61</xref>], why the authors suggest this might be an
additional disease sign.</p>
</sec>
<sec id="Sec10">
<title>RAB39B</title>
<p id="Par30">In 2014, Wilson et al. reported deletions of the entire <italic>RAB39B</italic> gene on the X chromosome in an Australian family
with three affected brothers [<xref ref-type="bibr" rid="CR62">62</xref>••].
These individuals had intellectual disability from birth with delayed speech
initiation and early learning difficulties in all three, to a degree that
independent living was impossible. One individual also had delayed early motor
milestones as well as obsessional and ritualistic behavior [<xref ref-type="bibr" rid="CR62">62</xref>••]. Tremor was noted from late childhood in
one of the three brothers, and the other two had tremor by age 38 and 44
subsequently developed akinetic-rigid Parkinsonism which was responsive to
levodopa. One of these patients with Parkinsonism had side effects to treatment,
and mild T2 MRI signal changes in the substantia nigra and globus pallidum that
were interpreted as deposition of iron or calcium. This individual came to autopsy
at age 48, which revealed cell loss and alpha-synuclein-positive Lewy bodies in
the substantia nigra as well as an abundance of cortical alpha-synuclein-positive
Lewy bodies. Also, there were some tau-positive neurofibrillary tangles in the
substantia nigra, and rare axonal spheroids in the white matter tracts of the
basal ganglia area [<xref ref-type="bibr" rid="CR62">62</xref>••]. The
pathology of this patient was thus compatible with the pathology that typically
defines PD [<xref ref-type="bibr" rid="CR63">63</xref>], and added <italic>RAB39B</italic>-related disease to the list of synucleinopathies
[<xref ref-type="bibr" rid="CR64">64</xref>].</p>
<p id="Par31">Wilson et al. also found c.503C&gt;A (p.T168K) mutations in the
<italic>RAB39B</italic> gene in a large family from Wisconsin,
USA, where seven male members from one generation were affected. The Wisconsin
family was originally described in 1985, and all affected members had intellectual
disability, persistent frontal lobe reflexes, tremor, rigidity, and Parkinsonian
postural abnormalities [<xref ref-type="bibr" rid="CR65">65</xref>].
Seizures, strabismus, and macrocephaly occurred in some members. By linkage
analysis, the genetic locus of the disorder in the Wisconsin family had been
narrowed down to the distal long arm of the X chromosome [<xref ref-type="bibr" rid="CR66">66</xref>], where <italic>RAB39B</italic> is located.</p>
<p id="Par32">Mutations in <italic>RAB39B</italic> had already
in 2010 been identified in (other) families with X-linked intellectual disability
associated with autism, epilepsy, and macrocephaly: In one large kindred
(designated MRX72) from Sardinia, Italy, eight male members displayed moderate to
severe intellectual disability and global delay of all psychomotor development,
three of whom had seizures and one an autism spectrum disorder [<xref ref-type="bibr" rid="CR67">67</xref>]. Affected members had previously been
reported to carry an intronic mutation, c.215+1G&gt;A, in a 5′ splice site of
<italic>RAB39B</italic> that affects normal splicing and
disrupts protein biosynthesis [<xref ref-type="bibr" rid="CR68">68</xref>]. A
second family (named Fam. X, or D-23) carried <italic>RAB39B</italic> c.21C&gt;A (p.Y7X) mutations that introduce an early stop
codon [<xref ref-type="bibr" rid="CR68">68</xref>]; six members in two
generation had mild to severe intellectual disability and macrocephaly, two of
which had autism, and four had short stature [<xref ref-type="bibr" rid="CR68">68</xref>]. Interestingly, duplications and triplications of <italic>RAB39B</italic> lead to intellectual disability and behavioral
disturbances; these mutations have been described in children, some of whom also
had mild motor symptoms or reached milestones of motor development late
[<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. However, no parkinsonian features were reported from any of
these families.</p>
<p id="Par33">Additional individuals and families with <italic>RAB39B</italic> and Parkinsonism have been described: <italic>RAB39B</italic> c.574G&gt;A (p.G192R) mutations co-segregated with disease in
a large US family of European origin [<xref ref-type="bibr" rid="CR71">71</xref>], compatible with X-linked dominant inheritance. Seven
affected members had Parkinsonism with symptoms developing between 29 and 53 years
in five males and at 55 and 57 in two females. Heterozygous mutations were found
in females who were clinically unaffected, seen as evidence for incomplete
penetrance and later disease onset in female compared to male mutation carriers.
Mild lifelong intellectual disability was documented for two of the affected
members, but not for the other; however, the article refrains from describing the
methods for clinical assessment, and mostly typical PD motor manifestations are
described. Based on the published information, it cannot be excluded with
certainty that more detailed investigations for non-motor signs, or psychological
assessment, would have revealed intellectual disabilities in these patients as
well.</p>
<p id="Par34">
<italic>RAB39B</italic> c.536dupA (p.E179fsX48) was identified
in a small Chinese family with two male patients who had learning difficulty from
childhood and mild intellectual disability [<xref ref-type="bibr" rid="CR72">72</xref>]. Both developed tremor and rigidity at age 10 and 12 years,
progressing to moderate or severe PD by ages 20 and 58 years. Levodopa treatment
had a mild effect on the younger patient but not the older one. The older
individual had severe cognitive decline at age 58. Both patients showed
calcifications of the globus pallidus in CT.</p>
<p id="Par35">
<italic>RAB39B</italic> mutations have also been found in
additional single individuals [<xref ref-type="bibr" rid="CR71">71</xref>,
<xref ref-type="bibr" rid="CR73">73</xref>]. Detailed clinical information
is provided on one French patient with <italic>RAB39B</italic>
c.557G&gt;A (p.W186X) who had mild intellectual disability, requiring sheltered
employment, and who developed asymmetric tremor at rest and akinetic-rigid
Parkinsonism at age 39 years. By age 47, he had developed motor fluctuations,
dyskinesia, and dystonia, and dysthymia with impulsiveness to a degree that he was
considered unsuitable for DBS surgery [<xref ref-type="bibr" rid="CR73">73</xref>].</p>
<p id="Par36">Thus, <italic>RAB39B</italic> mutations are a
well-established cause for intellectual disability, and Parkinsonism, with
alpha-synuclein-positive pathology, was observed in some of these patients.</p>
<p id="Par37">The RAB39B mutations described in patients who developed
Parkinsonism are loss-of-function mutations. RAB39B belongs to the Rab GTPase
superfamily of proteins that regulate vesicular trafficking. RAB39B is present in
high amounts in neurons where it also appears to be involved in the vesicular
recycling pathways between the synaptic cell membrane, endosomes, and the
trans-Golgi network. Furthermore, RAB39B may have a role in maintaining
intraneuronal alpha-synuclein homeostasis [<xref ref-type="bibr" rid="CR62">62</xref>••, <xref ref-type="bibr" rid="CR68">68</xref>,
<xref ref-type="bibr" rid="CR71">71</xref>].</p>
</sec>
<sec id="Sec11">
<title>DNAJC6</title>
<p id="Par38">In 2012, Edvardson et al. described a homozygous intronic
c.801-2A&gt;G mutation in the <italic>DNAJC6</italic> gene that
affects normal splicing, in two affected siblings of a Palestinian family
[<xref ref-type="bibr" rid="CR74">74</xref>•]. The two patients had normal
early development, but signs of childhood-onset Parkinsonism were noted at the age
of 7 and 11 years. Both patients soon developed severe and debilitating disease
with pronounced bradykinesia, rigidity, postural instability, and rest tremor, and
both were unable to walk at age 13 and 18 years. Pharmacological treatment
attempts were made with several types of dopaminergic medication but did not
improve symptoms. Hypometric saccades were noted in one of the patients.</p>
<p id="Par39">Subsequently, the truncating mutation c.2200C&gt;T (p.Q734X) was
found in four affected members of a consanguineous Turkish kindred [<xref ref-type="bibr" rid="CR75">75</xref>]. These individuals had a severe disease with
mild to moderate intellectual disability, seizures (in three individuals),
Parkinsonism, and pyramidal signs. Age at onset was 10 to 11 years, and all four
patients became wheelchair bound or bedridden in their 20s. Motor symptoms
included resting and postural tremor, bradykinesia, rigidity, and intermittent
dystonia. Levodopa (62.5 mg) had good effect on these symptoms but caused severe
motor and psychiatric side effects. A patient who underwent MRI scanning in his
40s had diffuse brain atrophy. Two patients each had scoliosis and myoclonus
[<xref ref-type="bibr" rid="CR75">75</xref>].</p>
<p id="Par40">By sequencing the <italic>DNAJC6</italic> gene in
patients with early-onset PD, Olgiati et al. discovered three patients with double
mutations in this gene [<xref ref-type="bibr" rid="CR76">76</xref>••]. Two of
them had familial disease, and analysis of affected and unaffected family members
showed complete co-segregation. Moreover, homozygosity analysis and whole-exome
sequencing supported the contention that the <italic>DNAJC6</italic> mutations were disease-causing. One Dutch family carried
<italic>DNAJC6</italic> c.2779A&gt;G (p.R927G) mutations, and
one Brazilian family the c.2223A&gt;T mutation that is not predicted to cause any
amino acid change, but there was good evidence that it may affect splicing.
Patients developed hand tremor and/or motor slowness at ages between 21 and
42 years. Bradykinesia, rigidity, and postural instability ensued in all four, and
rest tremor in three of them. The disease progressed, motor fluctuations
developed, and the oldest patient was bound to a wheelchair at 48 years of age.
All had good effect of levodopa, but three of the patients developed
levodopa-induced hallucinations. In contrast to most of the previously described
patients with <italic>DNAJC6</italic> mutations, no intellectual
disability was noted. However, one patient required neuroleptic treatment at age
21 because of psychosis, and Parkinsonism developed at this age as a side effect
[<xref ref-type="bibr" rid="CR76">76</xref>••].</p>
<p id="Par41">In one patient of Sudanese family with Yemeni origin, a homozygous
<italic>DNAJC6</italic> c.2365C&gt;T (p.Q789*) was found;
there were no additional affected family members, but the four unaffected members
examined genetically did not share the same genotype [<xref ref-type="bibr" rid="CR77">77</xref>]. The patient started to have terrifying
visual hallucinations at age 10.5 years, followed by rapidly deteriorating
cognition and motor function. Severe rigidity and resting tremor developed, as
well as pyramidal signs, and the patient started to have epileptic seizures, and
additional psychotic features. Motor function also deteriorated rapidly; at age
12.5, the patient was almost entirely akinetic.</p>
<p id="Par42">
<italic>DNAJC6</italic> is thus a well-established cause of
Parkinsonism with childhood onset, often associated with cognitive or psychiatric
symptoms. However, a genotype-phenotype effect has been observed where mutations
that have a large impact on protein function lead to very severe, early-onset
disease, and mutations that affect protein function more mildly cause adult
early-onset PD with few, or no, additional signs and symptoms [<xref ref-type="bibr" rid="CR76">76</xref>••, <xref ref-type="bibr" rid="CR78">78</xref>].</p>
</sec>
<sec id="Sec12">
<title>VPS13C</title>
<p id="Par43">Also in 2016, Lesage et al. reported three apparently sporadic
patients with mutations in <italic>VPS13C</italic> [<xref ref-type="bibr" rid="CR79">79</xref>••]. The first mutation, homozygous
c.8445+2T&gt;G, was identified in a Turkish patient by homozygosity linkage
mapping and exome sequencing of consanguineous families with early-onset
Parkinsonism. Two additional patients from France were compound heterozygous for
mutations in <italic>VPS13C</italic>,
c.806_807insCAGA/c.9568G&gt;T (p.R269Sfs*14/p.E3190*), and c.4165G&gt;C/c.4777delC
(p.G1389R/p.Q1593Kfs*7). The patients all had a relatively similar clinical
presentation with an asymmetric akinetic rigid syndrome starting at 25, 33, and
before 46 years of age. There was initial or partial effect of levodopa treatment,
and two of the patients developed motor fluctuations or dyskinesias. However,
progression was rapid and severe. All three patients developed severe and early
cognitive dysfunction; two each had dysautonomia or limb dystonia. All patients
were bedridden at 31, 43, and 58 years of age, and two developed dysphagia. All
three had pyramidal signs or symptoms with hyperreflexia, limb atrophy, or spastic
tetraplegia. MRI of the homozygous patients showed asymmetric cerebral atrophy.
Neuropathology of one of the patients who died after a 16-year disease duration
revealed mild frontal atrophy, and widespread and abundant
alpha-synuclein-positive Lewy bodies and neurites, resembling diffuse Lewy body
disease. In addition, there was widespread tau-pathology with neurofibrillary
tangles. The mutations have been shown to alter mitochondrial function and
PINK1/parkin-dependent mitophagy, and to upregulate the response of parkin to
mitochondrial damage [<xref ref-type="bibr" rid="CR79">79</xref>••].</p>
</sec>
<sec id="Sec13">
<title>PODXL</title>
<p id="Par44">In an Indian family with three affected siblings from the state of
Uttar Pradesh, Sudhaman et al. recently identified a homozygous frameshift
<italic>PODXL</italic> c.89_90insGTCGCCCC that results in
complete loss of PODXL protein [<xref ref-type="bibr" rid="CR80">80</xref>].
Patients developed levodopa-responsive Parkinsonism at 13–17 years of age,
developed dyskinesia and off-dystonia, and showed no obvious additional signs.
Five additional unaffected siblings as well as the unaffected, consanguineous
parents were either heterozygous or did not carry the mutation, which was shown to
influence neuronal branching. Confirmation of these findings in independent
patients and families is awaited.</p>
</sec>
<sec id="Sec14">
<title>PTRHD1</title>
<p id="Par45">Two independent reports from Iran have linked <italic>PTRHD1</italic> (<italic>C2ORF79</italic>) to
recessive Parkinsonism. Khodadadi et al. detected homozygous <italic>PTRHD1</italic> c.157C&gt;T (p.H53Y) mutations in two siblings
with intellectual disability and motor abnormalities from childhood, who developed
muscle stiffness, resting and postural tremor, and anxiety, hypersomnia, and
hypersexuality [<xref ref-type="bibr" rid="CR81">81</xref>••]. Parkinsonism
developed as a relatively late part of that syndrome in the late 20s to 30s and
was improved by levodopa in daily doses of 300 to 450 mg. Jaberi et al. described
a second family with two brothers who had a similar clinical presentation
[<xref ref-type="bibr" rid="CR82">82</xref>]. The patients had developed
gait disturbance, slowness of movements, tremor, and falls in the mid-20s.
Neurological examination yielded parkinsonian signs but also distal muscular
atrophy and weakness, hyperreflexia and positive Babinski sign, and evidence for
axonal sensorimotor polyneuropathy. One of the patients had severe intellectual
disability, the other one attention deficits, difficulty concentrations, and
perseveration of speech. Genetic analyses of the second family identified two
possible disease causes: one was a mutation in <italic>ADORA1</italic>, and the other one c.155G&gt;A (p.C52Y) in <italic>PTRHD1</italic>. Jaberi et al. attributed the disorder to
<italic>ADORA1</italic>, but Khodadadi et al. subsequently
considered the mutations in <italic>PTRHD1</italic>, affecting
the same protein domain and present in both families with similar clinical
pictures, as the true cause of the disease also in the family described by Jaberi
et al. Microdeletions of the locus including the <italic>PTRHD1</italic> gene are known causes of syndromes with intellectual
disability [<xref ref-type="bibr" rid="CR81">81</xref>••]. Further
confirmation in additional families is desirable.</p>
</sec>
</sec>
<sec id="Sec15">
<title>Conclusion</title>
<p id="Par46">A large body of work has nominated several new genes for dominant,
recessive, and X-linked PD or Parkinsonism during recent years, and high-throughput
technologies such as exome sequencing will continue to suggest new genetic causes in
the near future. Some of the genes have been connected to PD or Parkinsonism by a
solid body of evidence with observations of the mutation’s co-segregation with
clinically similar disease subtype in more than one family. Other, more recently
identified or rarer mutations await confirmation. There have been instances where
initially suggested genes turned out to be—most probably—not pathogenic after
subsequent studies, including the diverging observations on <italic>EIF4G1</italic> mutations in PD patients and healthy subjects [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>],
as well as the initial identification of <italic>ADORA1</italic>
as disease-causing mutations [<xref ref-type="bibr" rid="CR82">82</xref>] in a
family who also have <italic>PTRHD1</italic> mutations, and there
is ongoing uncertainty on the truly pathogenic variant in the large Canadian
Mennonite kindred discussed above, where <italic>DNAJC13</italic>
and <italic>TMEM230</italic> mutations have been postulated to be
disease-causing [<xref ref-type="bibr" rid="CR7">7</xref>••, <xref ref-type="bibr" rid="CR28">28</xref>••]. Clinicians need to be aware of possible
uncertainties in our present knowledge on these newly discovered genetic entities
when providing genetic counseling to patients and families with monogenic forms of
PD or Parkinsonism.</p>
<p id="Par47">Several of the genes discussed above do not cause PD but syndromes
with Parkinsonism and other characteristic signs. Despite the addition of these
newly identified genes to our lists of PD genes, the majority of cases of familial
aggregation of PD remain unexplained, and the search for a monogenic cause for PD in
many such families has not been fruitful despite large effort [<xref ref-type="bibr" rid="CR83">83</xref>]. Alternative explanations may include digenic
or oligogenic inheritance, where two or a few genetic variants have a pathogenic
effect when they occur together in individuals and some of their relatives
[<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR85">85</xref>••]. Such variants need not be extremely rare, and may have an
intermediate effect size, so that they by themselves do not cause disease, but will
be pathogenic in combination with other genetic variants. They may be in newly
discovered genes or in genes that also harbor disease-causing mutations, such as the
PINK1 p.G411S variants for whom we and others recently have shown that they markedly
increase PD risk, but are not per se disease-causing in all carriers [<xref ref-type="bibr" rid="CR86">86</xref>–<xref ref-type="bibr" rid="CR88">88</xref>]. One example of an interaction between two
genetic variants has recently been identified, whereby genetic variation in
<italic>DNM3</italic> modifies the effect of the common LRRK2
p.G2019S mutations [<xref ref-type="bibr" rid="CR89">89</xref>]. Research
networks with exome or whole-genome data from a large number of patients can be
predicted to identify many additional similar variants and complex gene-gene
interactions, gradually filling the gap of “missing heritability” in idiopathic
PD.</p>
</sec>
</body>
<back>
<fn-group>
<fn>
<p>This article is part of the Topical Collection on <italic>Genetics</italic>
</p>
</fn>
</fn-group>
<notes notes-type="COI-statement">
<title>Compliance with Ethical Standards</title>
<sec id="FPar1">
<title>Conflict of Interest</title>
<p id="Par48">Andreas Puschmann declares no conflict of interest.</p>
</sec>
<sec id="FPar2">
<title>Human and Animal Rights and Informed Consent</title>
<p id="Par49">This article does not contain any studies with human or animal
subjects performed by any of the authors.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref-list id="BSec1">
<title>Papers of particular interest, published recently, have been highlighted
as: • Of importance •• Of major importance</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonifati</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Genetics of Parkinson’s disease—state of the art,
2013</article-title>
<source/>Parkinsonism Relat Disord
            <year>2014</year>
<volume>20</volume>
<issue>Suppl 1</issue>
<fpage>S23</fpage>
<lpage>S28</lpage>
<pub-id pub-id-type="doi">10.1016/S1353-8020(13)70009-9</pub-id>
<pub-id pub-id-type="pmid">24262182</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puschmann</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Monogenic Parkinson’s disease and parkinsonism:
clinical phenotypes and frequencies of known mutations</article-title>
<source/>Parkinsonism Relat Disord
            <year>2013</year>
<volume>19</volume>
<issue>4</issue>
<fpage>407</fpage>
<lpage>415</lpage>
<pub-id pub-id-type="doi">10.1016/j.parkreldis.2013.01.020</pub-id>
<pub-id pub-id-type="pmid">23462481</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singleton</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Farrer</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Bonifati</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>The genetics of Parkinson’s disease: progress and
therapeutic implications</article-title>
<source/>Mov Disord
            <year>2013</year>
<volume>28</volume>
<issue>1</issue>
<fpage>14</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.1002/mds.25249</pub-id>
<pub-id pub-id-type="pmid">23389780</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<mixed-citation publication-type="other">Puschmann A, Wszolek Z. Genotype-phenotype correlations in
Parkinson disease. In: LeDoux MS, editor. Movement disorders: genetics and
models. 2 ed. Elsevier; 2013.</mixed-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lill</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>Genetics of Parkinson’s disease</article-title>
<source/>Mol Cell Probes
            <year>2016</year>
<volume>30</volume>
<issue>6</issue>
<fpage>386</fpage>
<lpage>396</lpage>
<pub-id pub-id-type="doi">10.1016/j.mcp.2016.11.001</pub-id>
<pub-id pub-id-type="pmid">27818248</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferreira</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Massano</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>An updated review of Parkinson’s disease genetics
and clinicopathological correlations</article-title>
<source/>Acta Neurol Scand
            <year>2017</year>
<volume>135</volume>
<issue>3</issue>
<fpage>273</fpage>
<lpage>284</lpage>
<pub-id pub-id-type="doi">10.1111/ane.12616</pub-id>
<pub-id pub-id-type="pmid">27273099</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vilarino-Guell</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rajput</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Milnerwood</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Szu-Tu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Trinh</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>DNAJC13 mutations in Parkinson
disease</article-title>
<source/>Hum Mol Genet
            <year>2014</year>
<volume>23</volume>
<issue>7</issue>
<fpage>1794</fpage>
<lpage>1801</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddt570</pub-id>
<pub-id pub-id-type="pmid">24218364</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gustavsson</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Trinh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Guella</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Vilarino-Guell</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Appel-Cresswell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stoessl</surname>
<given-names>AJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>DNAJC13 genetic variants in
parkinsonism</article-title>
<source/>Mov Disord
            <year>2015</year>
<volume>30</volume>
<issue>2</issue>
<fpage>273</fpage>
<lpage>278</lpage>
<pub-id pub-id-type="doi">10.1002/mds.26064</pub-id>
<pub-id pub-id-type="pmid">25393719</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foo</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Liany</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Au</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>Prakash</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>DNAJ mutations are rare in Chinese Parkinson’s
disease patients and controls</article-title>
<source/>Neurobiol Aging
            <year>2014</year>
<volume>35</volume>
<issue>4</issue>
<fpage>935.e1</fpage>
<lpage>935.e2</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2013.09.018</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lorenzo-Betancor</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Ogaki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Soto-Ortolaza</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Labbe</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Walton</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Strongosky</surname>
<given-names>AJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>DNAJC13 p.Asn855Ser mutation screening in
Parkinson’s disease and pathologically confirmed Lewy body disease
patients</article-title>
<source/>Eur J Neurol
            <year>2015</year>
<volume>22</volume>
<issue>9</issue>
<fpage>1323</fpage>
<lpage>1325</lpage>
<pub-id pub-id-type="doi">10.1111/ene.12770</pub-id>
<pub-id pub-id-type="pmid">26278106</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ross</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Dupre</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dauvilliers</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Strong</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ambalavanan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Spiegelman</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Analysis of DNAJC13 mutations in
French-Canadian/French cohort of Parkinson's disease</article-title>
<source/>Neurobiol Aging
            <year>2016</year>
<volume>45</volume>
<fpage>212.e13</fpage>
<lpage>212.e17</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2016.04.023</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Appel-Cresswell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rajput</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Sossi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>V</given-names>
</name>
<name>
<surname>McKenzie</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical, positron emission tomography, and
pathological studies of DNAJC13 p.N855S parkinsonism</article-title>
<source/>Mov Disord
            <year>2014</year>
<volume>29</volume>
<issue>13</issue>
<fpage>1684</fpage>
<lpage>1687</lpage>
<pub-id pub-id-type="doi">10.1002/mds.26019</pub-id>
<pub-id pub-id-type="pmid">25186792</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Funayama</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ohe</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Amo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Furuya</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Yamaguchi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Saiki</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CHCHD2 mutations in autosomal dominant late-onset
Parkinson’s disease: a genome-wide linkage and sequencing study</article-title>
<source/>Lancet Neurol
            <year>2015</year>
<volume>14</volume>
<issue>3</issue>
<fpage>274</fpage>
<lpage>282</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(14)70266-2</pub-id>
<pub-id pub-id-type="pmid">25662902</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CHCHD2 gene mutations in familial and sporadic
Parkinson’s disease</article-title>
<source/>Neurobiol Aging
            <year>2016</year>
<volume>38</volume>
<fpage>217 e9</fpage>
<lpage>217 13</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2015.10.040</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mao</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>YT</given-names>
</name>
<name>
<surname>Zuo</surname>
<given-names>CT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brain glucose metabolism changes in Parkinson’s
disease patients with CHCHD2 mutation based on (18)F-FDG PET
imaging</article-title>
<source/>J Neurol Sci
            <year>2016</year>
<volume>369</volume>
<fpage>303</fpage>
<lpage>305</lpage>
<pub-id pub-id-type="doi">10.1016/j.jns.2016.08.042</pub-id>
<pub-id pub-id-type="pmid">27653913</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koschmidder</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Weissbach</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bruggemann</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kasten</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lohmann</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>A nonsense mutation in CHCHD2 in a patient with
Parkinson disease</article-title>
<source/>Neurology
            <year>2016</year>
<volume>86</volume>
<issue>6</issue>
<fpage>577</fpage>
<lpage>579</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0000000000002361</pub-id>
<pub-id pub-id-type="pmid">26764027</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jansen</surname>
<given-names>IE</given-names>
</name>
<name>
<surname>Bras</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Lesage</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schulte</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gibbs</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Nalls</surname>
<given-names>MA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CHCHD2 and Parkinson’s disease</article-title>
<source/>Lancet Neurol
            <year>2015</year>
<volume>14</volume>
<issue>7</issue>
<fpage>678</fpage>
<lpage>679</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(15)00094-0</pub-id>
<pub-id pub-id-type="pmid">26067110</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogaki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Koga</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Heckman</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Fiesel</surname>
<given-names>FC</given-names>
</name>
<name>
<surname>Ando</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Labbe</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial targeting sequence variants of the
CHCHD2 gene are a risk for Lewy body disorders</article-title>
<source/>Neurology
            <year>2015</year>
<volume>85</volume>
<issue>23</issue>
<fpage>2016</fpage>
<lpage>2025</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0000000000002170</pub-id>
<pub-id pub-id-type="pmid">26561290</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foo</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>EK</given-names>
</name>
</person-group>
<article-title>CHCHD2 and Parkinson’s disease</article-title>
<source/>Lancet Neurol
            <year>2015</year>
<volume>14</volume>
<issue>7</issue>
<fpage>681</fpage>
<lpage>682</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(15)00098-8</pub-id>
<pub-id pub-id-type="pmid">26067114</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gagliardi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Iannello</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Colica</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Annesi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Quattrone</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Analysis of CHCHD2 gene in familial Parkinson’s
disease from Calabria</article-title>
<source/>Neurobiol Aging
            <year>2017</year>
<volume>50</volume>
<fpage>169 e5</fpage>
<lpage>169 e6</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2016.10.022</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puschmann</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dickson</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Englund</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wszolek</surname>
<given-names>ZK</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>OA</given-names>
</name>
</person-group>
<article-title>CHCHD2 and Parkinson’s disease</article-title>
<source/>Lancet Neurol
            <year>2015</year>
<volume>14</volume>
<issue>7</issue>
<fpage>679</fpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(15)00095-2</pub-id>
<pub-id pub-id-type="pmid">26067111</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>He</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutation analysis of CHCHD2 gene in Chinese Han
familial essential tremor patients and familial Parkinson’s disease
patients</article-title>
<source/>Neurobiol Aging
            <year>2017</year>
<volume>49</volume>
<fpage>218 e9</fpage>
<lpage>218e11</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2016.10.001</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tejera-Parrado</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jesus</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Huertas-Fernandez</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bernal-Bernal</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bonilla-Toribio</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cordoba-Tevar</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic analysis of CHCHD2 in a southern Spanish
population</article-title>
<source/>Neurobiol Aging
            <year>2017</year>
<volume>50</volume>
<fpage>169 e1</fpage>
<lpage>169 e2</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2016.10.019</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Xi</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ghani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Moreno</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutation analysis of CHCHD2 in Canadian patients
with familial Parkinson’s disease</article-title>
<source/>Neurobiol Aging
            <year>2016</year>
<volume>38</volume>
<fpage>217 e7</fpage>
<lpage>217 e8</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2015.10.038</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rubino</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Brusa</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Boschi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Govone</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Vacca</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic analysis of CHCHD2 and CHCHD10 in Italian
patients with Parkinson’s disease</article-title>
<source/>Neurobiol Aging
            <year>2017</year>
<volume>53</volume>
<fpage>193 e7</fpage>
<lpage>193 e8</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2016.12.027</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sudhaman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Muthane</surname>
<given-names>UB</given-names>
</name>
<name>
<surname>Behari</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Govindappa</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Juyal</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Thelma</surname>
<given-names>BK</given-names>
</name>
</person-group>
<article-title>Evidence of mutations in RIC3 acetylcholine receptor
chaperone as a novel cause of autosomal-dominant Parkinson’s disease with
non-motor phenotypes</article-title>
<source/>J Med Genet
            <year>2016</year>
<volume>53</volume>
<issue>8</issue>
<fpage>559</fpage>
<lpage>566</lpage>
<pub-id pub-id-type="doi">10.1136/jmedgenet-2015-103616</pub-id>
<pub-id pub-id-type="pmid">27055476</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ross</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Dupre</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dauvilliers</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Strong</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dionne-Laporte</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dion</surname>
<given-names>PA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>RIC3 variants are not associated with Parkinson’s
disease in French-Canadians and French</article-title>
<source/>Neurobiol Aging
            <year>2017</year>
<volume>53</volume>
<fpage>194 e9</fpage>
<lpage>194e11</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2017.01.005</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>HX</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ahmeti</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of TMEM230 mutations in familial
Parkinson’s disease</article-title>
<source/>Nat Genet
            <year>2016</year>
<volume>48</volume>
<issue>7</issue>
<fpage>733</fpage>
<lpage>739</lpage>
<pub-id pub-id-type="doi">10.1038/ng.3589</pub-id>
<pub-id pub-id-type="pmid">27270108</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<mixed-citation publication-type="other">Mandemakers W, Quadri M, Stamelou M, Bonifati V. TMEM230: how
does it fit in the etiology and pathogenesis of Parkinson’s disease. Mov Disord.
2017; doi:10.1002/mds.27061.</mixed-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giri</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mok</surname>
<given-names>KY</given-names>
</name>
<name>
<surname>Jansen</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tesson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mangone</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lack of evidence for a role of genetic variation in
TMEM230 in the risk for Parkinson’s disease in the Caucasian
population</article-title>
<source/>Neurobiol Aging
            <year>2017</year>
<volume>50</volume>
<fpage>167 e11</fpage>
<lpage>167 e13</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2016.10.004</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Q</given-names>
</name>
<etal></etal>
</person-group>
<article-title>TMEM230 mutation analysis in Parkinson’s disease in
a Chinese population</article-title>
<source/>Neurobiol Aging
            <year>2017</year>
<volume>49</volume>
<fpage>219 e1</fpage>
<lpage>219 e3</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2016.10.007</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quadri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Breedveld</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Guedes</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Toni</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in TMEM230 are not a common cause of
Parkinson’s disease</article-title>
<source/>Mov Disord
            <year>2017</year>
<volume>32</volume>
<issue>2</issue>
<fpage>302</fpage>
<lpage>304</lpage>
<pub-id pub-id-type="doi">10.1002/mds.26900</pub-id>
<pub-id pub-id-type="pmid">28090676</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>ZH</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>SY</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic analysis of the TMEM230 gene in Chinese Han
patients with Parkinson’s disease</article-title>
<source/>Sci Rep
            <year>2017</year>
<volume>7</volume>
<issue>1</issue>
<fpage>1190</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-01398-9</pub-id>
<pub-id pub-id-type="pmid">28446760</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>An</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Xi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sequencing TMEM230 in Chinese patients with sporadic
or familial Parkinson’s disease</article-title>
<source/>Mov Disord
            <year>2017</year>
<volume>32</volume>
<issue>5</issue>
<fpage>800</fpage>
<lpage>802</lpage>
<pub-id pub-id-type="doi">10.1002/mds.26996</pub-id>
<pub-id pub-id-type="pmid">28370613</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Cen</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic analysis of the TMEM230 gene in Chinese
patients with familial Parkinson disease</article-title>
<source/>Parkinsonism Relat Disord
            <year>2017</year>
<volume>36</volume>
<fpage>105</fpage>
<lpage>106</lpage>
<pub-id pub-id-type="doi">10.1016/j.parkreldis.2016.12.021</pub-id>
<pub-id pub-id-type="pmid">28038866</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baumann</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wolff</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Munchau</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hagenah</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Lohmann</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Evaluating the role of TMEM230 variants in
Parkinson’s disease</article-title>
<source/>Parkinsonism Relat Disord
            <year>2017</year>
<volume>35</volume>
<fpage>100</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="doi">10.1016/j.parkreldis.2016.12.015</pub-id>
<pub-id pub-id-type="pmid">28017548</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>QQ</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>TMEM230 stop codon mutation is rare in Parkinson’s
disease and essential tremor in eastern China</article-title>
<source/>Mov Disord
            <year>2017</year>
<volume>32</volume>
<issue>2</issue>
<fpage>301</fpage>
<lpage>302</lpage>
<pub-id pub-id-type="doi">10.1002/mds.26875</pub-id>
<pub-id pub-id-type="pmid">27869322</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<mixed-citation publication-type="other">Ibanez L, Dube U, Budde J, Black K, Medvedeva A, Davis AA, et al.
TMEM230 in Parkinson’s disease. Neurobiol Aging. 2017; doi:10.1016/j.neurobiolaging.2017.03.014.</mixed-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buongarzone</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Monfrini</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Franco</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Trezzi</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Borellini</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Frattini</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in TMEM230 are rare in autosomal dominant
Parkinson’s disease</article-title>
<source/>Parkinsonism Relat Disord
            <year>2017</year>
<volume>39</volume>
<fpage>87</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="doi">10.1016/j.parkreldis.2017.03.007</pub-id>
<pub-id pub-id-type="pmid">28318986</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McDonald-McGinn</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Marino</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Philip</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Swillen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vorstman</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>22q11.2 deletion syndrome</article-title>
<source/>Nat Rev Dis Primers
            <year>2015</year>
<volume>1</volume>
<fpage>15071</fpage>
<pub-id pub-id-type="doi">10.1038/nrdp.2015.71</pub-id>
<pub-id pub-id-type="pmid">27189754</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krahn</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Maraganore</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Michels</surname>
<given-names>VV</given-names>
</name>
</person-group>
<article-title>Childhood-onset schizophrenia associated with
parkinsonism in a patient with a microdeletion of chromosome 22</article-title>
<source/>Mayo Clin Proc
            <year>1998</year>
<volume>73</volume>
<issue>10</issue>
<fpage>956</fpage>
<lpage>959</lpage>
<pub-id pub-id-type="doi">10.4065/73.10.956</pub-id>
<pub-id pub-id-type="pmid">9787744</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zaleski</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bassett</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Tam</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Shugar</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Chow</surname>
<given-names>EW</given-names>
</name>
<name>
<surname>McPherson</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>The co-occurrence of early onset Parkinson disease
and 22q11.2 deletion syndrome</article-title>
<source/>Am J Med Genet A
            <year>2009</year>
<volume>149A</volume>
<issue>3</issue>
<fpage>525</fpage>
<lpage>528</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.32650</pub-id>
<pub-id pub-id-type="pmid">19208384</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Booij</surname>
<given-names>J</given-names>
</name>
<name>
<surname>van Amelsvoort</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Boot</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Co-occurrence of early-onset Parkinson disease and
22q11.2 deletion syndrome: potential role for dopamine transporter
imaging</article-title>
<source/>Am J Med Genet A
            <year>2010</year>
<volume>152A</volume>
<issue>11</issue>
<fpage>2937</fpage>
<lpage>2938</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.33665</pub-id>
<pub-id pub-id-type="pmid">20949509</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butcher</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Kiehl</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Hazrati</surname>
<given-names>LN</given-names>
</name>
<name>
<surname>Chow</surname>
<given-names>EW</given-names>
</name>
<name>
<surname>Rogaeva</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>AE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association between early-onset Parkinson disease
and 22q11.2 deletion syndrome: identification of a novel genetic form of
Parkinson disease and its clinical implications</article-title>
<source/>JAMA Neurol
            <year>2013</year>
<volume>70</volume>
<issue>11</issue>
<fpage>1359</fpage>
<lpage>1366</lpage>
<pub-id pub-id-type="doi">10.1001/jamaneurol.2013.3646</pub-id>
<pub-id pub-id-type="pmid">24018986</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rehman</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Dhamija</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Barrett</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>22q11.2 deletion syndrome presenting with
early-onset Parkinson’s disease</article-title>
<source/>Mov Disord
            <year>2015</year>
<volume>30</volume>
<issue>9</issue>
<fpage>1289</fpage>
<lpage>1290</lpage>
<pub-id pub-id-type="doi">10.1002/mds.26305</pub-id>
<pub-id pub-id-type="pmid">26195290</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boot</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Butcher</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>van Amelsvoort</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Marras</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pondal</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Movement disorders and other motor abnormalities in
adults with 22q11.2 deletion syndrome</article-title>
<source/>Am J Med Genet A
            <year>2015</year>
<volume>167a</volume>
<issue>3</issue>
<fpage>639</fpage>
<lpage>645</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.36928</pub-id>
<pub-id pub-id-type="pmid">25684639</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foo</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>EK</given-names>
</name>
</person-group>
<article-title>Large 3-Mb deletions at 22q11.2 locus in Parkinson’s
disease and schizophrenia</article-title>
<source/>Mov Disord
            <year>2016</year>
<volume>31</volume>
<issue>12</issue>
<fpage>1924</fpage>
<lpage>1925</lpage>
<pub-id pub-id-type="doi">10.1002/mds.26822</pub-id>
<pub-id pub-id-type="pmid">27787935</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hori</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Asayama</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wate</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kaneko</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kusaka</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Early-onset Parkinson’s disease associated with
chromosome 22q11.2 deletion syndrome</article-title>
<source/>Intern Med
            <year>2016</year>
<volume>55</volume>
<issue>3</issue>
<fpage>303</fpage>
<lpage>305</lpage>
<pub-id pub-id-type="doi">10.2169/internalmedicine.55.5485</pub-id>
<pub-id pub-id-type="pmid">26831029</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pollard</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hannan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tanabe</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Berman</surname>
<given-names>BD</given-names>
</name>
</person-group>
<article-title>Early-onset Parkinson disease leading to diagnosis
of 22q11.2 deletion syndrome</article-title>
<source/>Parkinsonism Relat Disord
            <year>2016</year>
<volume>25</volume>
<fpage>110</fpage>
<lpage>111</lpage>
<pub-id pub-id-type="doi">10.1016/j.parkreldis.2016.01.027</pub-id>
<pub-id pub-id-type="pmid">26868161</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mok</surname>
<given-names>KY</given-names>
</name>
<name>
<surname>Sheerin</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Simon-Sanchez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Salaka</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chester</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Escott-Price</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Deletions at 22q11.2 in idiopathic Parkinson’s
disease: a combined analysis of genome-wide association data</article-title>
<source/>Lancet Neurol
            <year>2016</year>
<volume>15</volume>
<issue>6</issue>
<fpage>585</fpage>
<lpage>596</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(16)00071-5</pub-id>
<pub-id pub-id-type="pmid">27017469</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogaki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>OA</given-names>
</name>
</person-group>
<article-title>Chromosome 22q11.2 deletion may contain a locus for
recessive early-onset Parkinson’s disease</article-title>
<source/>Parkinsonism Relat Disord
            <year>2014</year>
<volume>20</volume>
<issue>9</issue>
<fpage>945</fpage>
<lpage>946</lpage>
<pub-id pub-id-type="doi">10.1016/j.parkreldis.2014.06.020</pub-id>
<pub-id pub-id-type="pmid">25001314</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quadri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Picillo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Olgiati</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Breedveld</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Graafland</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutation in the SYNJ1 gene associated with autosomal
recessive, early-onset parkinsonism</article-title>
<source/>Hum Mutat
            <year>2013</year>
<volume>34</volume>
<issue>9</issue>
<fpage>1208</fpage>
<lpage>1215</lpage>
<pub-id pub-id-type="doi">10.1002/humu.22373</pub-id>
<pub-id pub-id-type="pmid">23804577</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krebs</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Karkheiran</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Powell</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Makarov</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Darvish</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The Sac1 domain of SYNJ1 identified mutated in a
family with early-onset progressive parkinsonism with generalized
seizures</article-title>
<source/>Hum Mutat
            <year>2013</year>
<volume>34</volume>
<issue>9</issue>
<fpage>1200</fpage>
<lpage>1207</lpage>
<pub-id pub-id-type="doi">10.1002/humu.22372</pub-id>
<pub-id pub-id-type="pmid">23804563</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Picillo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ranieri</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Orefice</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bonifati</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Barone</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Clinical progression of SYNJ1-related early onset
atypical parkinsonism: 3-year follow up of the original Italian
family</article-title>
<source/>J Neurol
            <year>2014</year>
<volume>261</volume>
<issue>4</issue>
<fpage>823</fpage>
<lpage>824</lpage>
<pub-id pub-id-type="doi">10.1007/s00415-014-7270-6</pub-id>
<pub-id pub-id-type="pmid">24532203</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olgiati</surname>
<given-names>S</given-names>
</name>
<name>
<surname>De Rosa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Quadri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Criscuolo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Breedveld</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Picillo</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PARK20 caused by SYNJ1 homozygous Arg258Gln mutation
in a new Italian family</article-title>
<source/>Neurogenetics
            <year>2014</year>
<volume>15</volume>
<issue>3</issue>
<fpage>183</fpage>
<lpage>188</lpage>
<pub-id pub-id-type="doi">10.1007/s10048-014-0406-0</pub-id>
<pub-id pub-id-type="pmid">24816432</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Rosa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pellegrino</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Pappata</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lieto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bonifati</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Palma</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Non-motor symptoms and cardiac innervation in
SYNJ1-related parkinsonism</article-title>
<source/>Parkinsonism Relat Disord
            <year>2016</year>
<volume>23</volume>
<fpage>102</fpage>
<lpage>105</lpage>
<pub-id pub-id-type="doi">10.1016/j.parkreldis.2015.12.006</pub-id>
<pub-id pub-id-type="pmid">26725142</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirola</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Behari</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shishir</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Thelma</surname>
<given-names>BK</given-names>
</name>
</person-group>
<article-title>Identification of a novel homozygous mutation
Arg459Pro in SYNJ1 gene of an Indian family with autosomal recessive juvenile
parkinsonism</article-title>
<source/>Parkinsonism Relat Disord
            <year>2016</year>
<volume>31</volume>
<fpage>124</fpage>
<lpage>128</lpage>
<pub-id pub-id-type="doi">10.1016/j.parkreldis.2016.07.014</pub-id>
<pub-id pub-id-type="pmid">27496670</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rauschendorf</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Jost</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stock</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zimmer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rosler</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Rijntjes</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Novel compound heterozygous synaptojanin-1 mutation
causes l-dopa-responsive dystonia-parkinsonism syndrome</article-title>
<source/>Mov Disord
            <year>2017</year>
<volume>32</volume>
<issue>3</issue>
<fpage>478</fpage>
<lpage>480</lpage>
<pub-id pub-id-type="doi">10.1002/mds.26876</pub-id>
<pub-id pub-id-type="pmid">27869329</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dyment</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Humphreys</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Schwartzentruber</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Beaulieu</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Bulman</surname>
<given-names>DE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Homozygous nonsense mutation in SYNJ1 associated
with intractable epilepsy and tau pathology</article-title>
<source/>Neurobiol Aging
            <year>2015</year>
<volume>36</volume>
<issue>2</issue>
<fpage>1222.e1</fpage>
<lpage>1222.e5</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2014.09.005</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hardies</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Jardel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jansen</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>M</given-names>
</name>
<name>
<surname>May</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Loss of SYNJ1 dual phosphatase activity leads to
early onset refractory seizures and progressive neurological
decline</article-title>
<source/>Brain
            <year>2016</year>
<volume>139</volume>
<issue>Pt 9</issue>
<fpage>2420</fpage>
<lpage>2430</lpage>
<pub-id pub-id-type="doi">10.1093/brain/aww180</pub-id>
<pub-id pub-id-type="pmid">27435091</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<mixed-citation publication-type="other">Taghavi S, Chaouni R, Tafakhori A, Azcona LJ, Firouzabadi SG,
Omrani MD, et al. A clinical and molecular genetic study of 50 families with
autosomal recessive parkinsonism revealed known and novel gene mutations. Mol
Neurobiol. 2017; doi:10.1007/s12035-017-0535-1.</mixed-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Sim</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>McLean</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Giannandrea</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Galea</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Riseley</surname>
<given-names>JR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in RAB39B cause X-linked intellectual
disability and early-onset Parkinson disease with alpha-synuclein
pathology</article-title>
<source/>Am J Hum Genet
            <year>2014</year>
<volume>95</volume>
<issue>6</issue>
<fpage>729</fpage>
<lpage>735</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2014.10.015</pub-id>
<pub-id pub-id-type="pmid">25434005</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dickson</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Braak</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Duda</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Duyckaerts</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gasser</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Halliday</surname>
<given-names>GM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuropathological assessment of Parkinson’s disease:
refining the diagnostic criteria</article-title>
<source/>Lancet Neurol
            <year>2009</year>
<volume>8</volume>
<issue>12</issue>
<fpage>1150</fpage>
<lpage>1157</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(09)70238-8</pub-id>
<pub-id pub-id-type="pmid">19909913</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puschmann</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bhidayasiri</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Weiner</surname>
<given-names>WJ</given-names>
</name>
</person-group>
<article-title>Synucleinopathies from bench to
bedside</article-title>
<source/>Parkinsonism Relat Disord
            <year>2012</year>
<volume>18</volume>
<issue>Suppl 1</issue>
<fpage>S24</fpage>
<lpage>S27</lpage>
<pub-id pub-id-type="doi">10.1016/S1353-8020(11)70010-4</pub-id>
<pub-id pub-id-type="pmid">22166445</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laxova</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Hogan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hecox</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Opitz</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>An X-linked recessive basal ganglia disorder with
mental retardation</article-title>
<source/>Am J Med Genet
            <year>1985</year>
<volume>21</volume>
<issue>4</issue>
<fpage>681</fpage>
<lpage>689</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.1320210409</pub-id>
<pub-id pub-id-type="pmid">4025396</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gregg</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Metzenberg</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Hogan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sekhon</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Laxova</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Waisman syndrome, a human X-linked recessive basal
ganglia disorder with mental retardation: localization to
Xq27.3-qter</article-title>
<source/>Genomics
            <year>1991</year>
<volume>9</volume>
<issue>4</issue>
<fpage>701</fpage>
<lpage>706</lpage>
<pub-id pub-id-type="doi">10.1016/0888-7543(91)90363-J</pub-id>
<pub-id pub-id-type="pmid">1674730</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Russo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cogliati</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cavalleri</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cassitto</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Giglioli</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Toniolo</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mapping to distal Xq28 of nonspecific X-linked
mental retardation MRX72: linkage analysis and clinical findings in a
three-generation Sardinian family</article-title>
<source/>Am J Med Genet
            <year>2000</year>
<volume>94</volume>
<issue>5</issue>
<fpage>376</fpage>
<lpage>382</lpage>
<pub-id pub-id-type="doi">10.1002/1096-8628(20001023)94:5&lt;376::AID-AJMG6&gt;3.0.CO;2-A</pub-id>
<pub-id pub-id-type="pmid">11050621</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giannandrea</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bianchi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Mignogna</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Sirri</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Carrabino</surname>
<given-names>S</given-names>
</name>
<name>
<surname>D'Elia</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in the small GTPase gene RAB39B are
responsible for X-linked mental retardation associated with autism, epilepsy,
and macrocephaly</article-title>
<source/>Am J Hum Genet
            <year>2010</year>
<volume>86</volume>
<issue>2</issue>
<fpage>185</fpage>
<lpage>195</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2010.01.011</pub-id>
<pub-id pub-id-type="pmid">20159109</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Hattab</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Gibson</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>GS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Int22h-1/int22h-2-mediated Xq28 rearrangements:
intellectual disability associated with duplications and in utero male
lethality with deletions</article-title>
<source/>J Med Genet
            <year>2011</year>
<volume>48</volume>
<issue>12</issue>
<fpage>840</fpage>
<lpage>850</lpage>
<pub-id pub-id-type="doi">10.1136/jmedgenet-2011-100125</pub-id>
<pub-id pub-id-type="pmid">21984752</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vanmarsenille</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Giannandrea</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fieremans</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Verbeeck</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Belet</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Raynaud</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased dosage of RAB39B affects neuronal
development and could explain the cognitive impairment in male patients with
distal Xq28 copy number gains</article-title>
<source/>Hum Mutat
            <year>2014</year>
<volume>35</volume>
<issue>3</issue>
<fpage>377</fpage>
<lpage>383</lpage>
<pub-id pub-id-type="doi">10.1002/humu.22497</pub-id>
<pub-id pub-id-type="pmid">24357492</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mata</surname>
<given-names>IF</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Hanna</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Dorschner</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Samii</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The RAB39B p.G192R mutation causes X-linked dominant
Parkinson’s disease</article-title>
<source/>Mol Neurodegener
            <year>2015</year>
<volume>10</volume>
<fpage>50</fpage>
<pub-id pub-id-type="doi">10.1186/s13024-015-0045-4</pub-id>
<pub-id pub-id-type="pmid">26399558</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>ZH</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shang</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>CY</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A novel RAB39B gene mutation in X-linked juvenile
parkinsonism with basal ganglia calcification</article-title>
<source/>Mov Disord
            <year>2016</year>
<volume>31</volume>
<issue>12</issue>
<fpage>1905</fpage>
<lpage>1909</lpage>
<pub-id pub-id-type="doi">10.1002/mds.26828</pub-id>
<pub-id pub-id-type="pmid">27943471</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lesage</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bras</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cormier-Dequaire</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Condroyer</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nicolas</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Darwent</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Loss-of-function mutations in RAB39B are associated
with typical early-onset Parkinson disease</article-title>
<source/>Neurol Genet
            <year>2015</year>
<volume>1</volume>
<issue>1</issue>
<fpage>e9</fpage>
<pub-id pub-id-type="doi">10.1212/NXG.0000000000000009</pub-id>
<pub-id pub-id-type="pmid">27066548</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edvardson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cinnamon</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ta-Shma</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shaag</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yim</surname>
<given-names>YI</given-names>
</name>
<name>
<surname>Zenvirt</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A deleterious mutation in DNAJC6 encoding the
neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with
juvenile parkinsonism</article-title>
<source/>PLoS One
            <year>2012</year>
<volume>7</volume>
<issue>5</issue>
<fpage>e36458</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0036458</pub-id>
<pub-id pub-id-type="pmid">22563501</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koroglu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Baysal</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cetinkaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Karasoy</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tolun</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>DNAJC6 is responsible for juvenile parkinsonism with
phenotypic variability</article-title>
<source/>Parkinsonism Relat Disord
            <year>2013</year>
<volume>19</volume>
<issue>3</issue>
<fpage>320</fpage>
<lpage>324</lpage>
<pub-id pub-id-type="doi">10.1016/j.parkreldis.2012.11.006</pub-id>
<pub-id pub-id-type="pmid">23211418</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olgiati</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Quadri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rood</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Saute</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Chien</surname>
<given-names>HF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>DNAJC6 mutations associated with early-onset
Parkinson’s disease</article-title>
<source/>Ann Neurol
            <year>2016</year>
<volume>79</volume>
<issue>2</issue>
<fpage>244</fpage>
<lpage>256</lpage>
<pub-id pub-id-type="doi">10.1002/ana.24553</pub-id>
<pub-id pub-id-type="pmid">26528954</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elsayed</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Drouet</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Usenko</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mohammed</surname>
<given-names>IN</given-names>
</name>
<name>
<surname>Hamed</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Elseed</surname>
<given-names>MA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A novel nonsense mutation in DNAJC6 expands the
phenotype of autosomal-recessive juvenile-onset Parkinson’s
disease</article-title>
<source/>Ann Neurol
            <year>2016</year>
<volume>79</volume>
<issue>2</issue>
<fpage>335</fpage>
<lpage>337</lpage>
<pub-id pub-id-type="doi">10.1002/ana.24591</pub-id>
<pub-id pub-id-type="pmid">26703368</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olgiati</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Quadri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mandemakers</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Bonifati</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Reply</article-title>
<source/>Ann Neurol
            <year>2016</year>
<volume>79</volume>
<issue>2</issue>
<fpage>337</fpage>
<lpage>338</lpage>
<pub-id pub-id-type="doi">10.1002/ana.24587</pub-id>
<pub-id pub-id-type="pmid">26702604</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lesage</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Drouet</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Majounie</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Deramecourt</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Jacoupy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nicolas</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Loss of VPS13C function in autosomal-recessive
parkinsonism causes mitochondrial dysfunction and increases
PINK1/parkin-dependent mitophagy</article-title>
<source/>Am J Hum Genet
            <year>2016</year>
<volume>98</volume>
<issue>3</issue>
<fpage>500</fpage>
<lpage>513</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2016.01.014</pub-id>
<pub-id pub-id-type="pmid">26942284</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sudhaman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Prasad</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Behari</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Muthane</surname>
<given-names>UB</given-names>
</name>
<name>
<surname>Juyal</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Thelma</surname>
<given-names>BK</given-names>
</name>
</person-group>
<article-title>Discovery of a frameshift mutation in
podocalyxin-like (PODXL) gene, coding for a neural adhesion molecule, as
causal for autosomal-recessive juvenile parkinsonism</article-title>
<source/>J Med Genet
            <year>2016</year>
<volume>53</volume>
<issue>7</issue>
<fpage>450</fpage>
<lpage>456</lpage>
<pub-id pub-id-type="doi">10.1136/jmedgenet-2015-103459</pub-id>
<pub-id pub-id-type="pmid">26864383</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khodadadi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Azcona</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Aghamollaii</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Omrani</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Garshasbi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Taghavi</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PTRHD1 (C2orf79) mutations lead to
autosomal-recessive intellectual disability and parkinsonism</article-title>
<source/>Mov Disord
            <year>2017</year>
<volume>32</volume>
<issue>2</issue>
<fpage>287</fpage>
<lpage>291</lpage>
<pub-id pub-id-type="doi">10.1002/mds.26824</pub-id>
<pub-id pub-id-type="pmid">27753167</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaberi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rohani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shahidi</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Nafissi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Arefian</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Soleimani</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutation in ADORA1 identified as likely cause of
early-onset parkinsonism and cognitive dysfunction</article-title>
<source/>Mov Disord
            <year>2016</year>
<volume>31</volume>
<issue>7</issue>
<fpage>1004</fpage>
<lpage>1011</lpage>
<pub-id pub-id-type="doi">10.1002/mds.26627</pub-id>
<pub-id pub-id-type="pmid">27134041</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puschmann</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pfeiffer</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Stoessl</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Kuriakose</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lash</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Searcy</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A family with parkinsonism, essential tremor,
restless legs syndrome, and depression</article-title>
<source/>Neurology
            <year>2011</year>
<volume>76</volume>
<issue>19</issue>
<fpage>1623</fpage>
<lpage>1630</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0b013e318219fb42</pub-id>
<pub-id pub-id-type="pmid">21555728</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hill-Burns</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>OA</given-names>
</name>
<name>
<surname>Wissemann</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Soto-Ortolaza</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Zareparsi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Siuda</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of genetic modifiers of age-at-onset
for familial Parkinson’s disease</article-title>
<source/>Hum Mol Genet
            <year>2016</year>
<volume>25</volume>
<issue>17</issue>
<fpage>3849</fpage>
<lpage>3862</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddw206</pub-id>
<pub-id pub-id-type="pmid">27402877</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<mixed-citation publication-type="other">•• Lubbe SJ, Escott-Price V, Gibbs JR, Nalls MA, Bras J, Price
TR, et al. Additional rare variant analysis in Parkinson’s disease cases with
and without known pathogenic mutations: evidence for oligogenic inheritance. Hum
Mol Genet. 2016; doi:10.1093/hmg/ddw348. <bold>Lubbe et al. used data from exome
sequencing and NeuroX analyses from 7900 PD cases to study possible oligogenic
mechanisms in PD.</bold></mixed-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gan-Or</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ruskey</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Spiegelman</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Arnulf</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Dauvilliers</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hogl</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Heterozygous PINK1 p.G411S in rapid eye movement
sleep behaviour disorder</article-title>
<source/>Brain
            <year>2017</year>
<volume>140</volume>
<issue>6</issue>
<fpage>e32</fpage>
<pub-id pub-id-type="doi">10.1093/brain/awx076</pub-id>
<pub-id pub-id-type="pmid">28379291</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puschmann</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fiesel</surname>
<given-names>FC</given-names>
</name>
<name>
<surname>Caulfield</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Hudec</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ando</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Truban</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Heterozygous PINK1 p.G411S increases risk of
Parkinson’s disease via a dominant-negative mechanism</article-title>
<source/>Brain
            <year>2017</year>
<volume>140</volume>
<issue>Pt 1</issue>
<fpage>98</fpage>
<lpage>117</lpage>
<pub-id pub-id-type="doi">10.1093/brain/aww261</pub-id>
<pub-id pub-id-type="pmid">27807026</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puschmann</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fiesel</surname>
<given-names>FC</given-names>
</name>
<name>
<surname>Caulfield</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Hudec</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ando</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Truban</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reply: heterozygous PINK1 p.G411S in rapid eye
movement sleep behaviour disorder</article-title>
<source/>Brain
            <year>2017</year>
<volume>140</volume>
<issue>6</issue>
<fpage>e33</fpage>
<pub-id pub-id-type="doi">10.1093/brain/awx077</pub-id>
<pub-id pub-id-type="pmid">28379295</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trinh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gustavsson</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Vilarino-Guell</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bortnick</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Latourelle</surname>
<given-names>J</given-names>
</name>
<name>
<surname>McKenzie</surname>
<given-names>MB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>DNM3 and genetic modifiers of age of onset in LRRK2
Gly2019Ser parkinsonism: a genome-wide linkage and association
study</article-title>
<source/>Lancet Neurol
            <year>2016</year>
<volume>15</volume>
<issue>12</issue>
<fpage>1248</fpage>
<lpage>1256</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(16)30203-4</pub-id>
<pub-id pub-id-type="pmid">27692902</pub-id>
</element-citation>
</ref>
</ref-list>
</ref-list>
</back>
</article>
</pmc-articleset>